11 – 20 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2001
-
Mark
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders
(
- Contribution to journal › Article
-
Mark
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values
(
- Contribution to journal › Article
-
Mark
Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype
(
- Contribution to journal › Article
- 2000
-
Mark
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma
(
- Contribution to journal › Article
-
Mark
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
(
- Contribution to journal › Article
- 1999
-
Mark
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »